# A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

> **NCT07543250** · — · NOT_YET_RECRUITING · sponsor: **xuliang** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Inavolisib in Combination With ET
- **DRUG:** Inavolisib in Combination With ET+CDK4/6i

## Key facts

- **NCT ID:** NCT07543250
- **Lead sponsor:** xuliang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-07-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543250, "A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07543250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*